PDS Biotechnology

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company based in North Brunswick, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. Founded in 2005, the company aims to prevent and treat various cancers, including cervical, ovarian, melanoma, leukemia, pancreatic, oral, multiple myeloma, anal, and vulvar cancers. PDS Biotechnology's product pipeline includes PDS0101, a treatment for HPV-related cancers; PDS0102, a pandemic influenza vaccine; and PDS0103, a series of immunotherapy products for non-viral cancers. The company's proprietary Versamune platform technology is designed to activate and direct the human immune system to effectively target and attack cancer cells, supporting its commitment to innovative cancer treatment solutions.